GLP1R and thyroid gland carcinoma: The findings of the as-treated analysis are consistent with an increased detection of thyroid cancer in the immediate period after starting GLP1 receptor agonist treatment, or other bias, given that a risk increase restricted to the first year of treatment is unlikely to be biologically plausible.